BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The European Collaborative Group On Prostate Brachytherapy Reports On Over 1,150 Patients Treated With ONCURA's RAPID Strand(TM)


10/19/2005 5:12:17 PM

LONDON, Nov. 24 /PRNewswire/ -- A paper describing the creation of a multi-centre database of 1,175 patients was published in a recent issue of the European Journal of Urology. As a global leader in minimally invasive prostate cancer treatment ONCURA supports the publication of data that demonstrates the value of prostate brachytherapy, and are pleased to announce that the paper indicates that prostate brachytherapy is a well established treatment option in many centres across Europe.

"The use of RAPID Strand and a consistent approach to patient selection has allowed us to pool our data and increase the significance of any results we see," said the lead author, Mr. Stephen Langley, Consultant Urologist at St. Luke's Cancer Centre (Guildford, UK). He added, "It is clear that the prostate brachytherapy approach adopted by the majority of centres in Europe lends itself to the collection and publication of data on a large number of patients."

The collaboration was aimed at examining European trends in the management of prostate cancer with brachytherapy. With harmonized data on 1,175 patients secured, valuable analysis of clinical outcomes is now possible and will be the subject of future publications.

"This is an excellent piece of research, one that exemplifies the multidisciplinary approach to the management of prostate cancer typically seen in Europe," said Elizabeth Usher, ONCURA's International Vice President and General Manager. She added, "ONCURA is proud to be associated with this project and we hope that in time more centres will be able to add their data and contribute to the wealth of excellent clinical data that supports the use of RAPID Strand in Europe."

ONCURA was created through the merger of Amersham plc's brachytherapy business and Galil Medical Ltd.'s urology business. Galil is a subsidiary of Elron (ELRN). Headquartered in the United States, ONCURA operates as an independent business, with a major presence in the treatment of prostate cancer. ONCURA's International business is operated from its UK subsidiary. On April 8, 2004, General Electric (GE) completed its previously announced acquisition of Amersham.

ONCURA

CONTACT: Andrew Bright, ONCURA, +1-484-530-3922,andrew.bright@oncura.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES